McDonald’s (NYSE:MCD) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsChris Kempczinski - Chairman and CEODave Palmer - Senior Managing Director and the Head of the Consumer Research TeamDexter Congbalay - VP of Investor RelationsIan Borden - CFOJill McDonald - Executive Vice President and President of International Operated MarketsConference Call ParticipantsAndrew Barish - Equity Research AnalystBrian Harbour - Equity Research AnalystDavid Tarantino - Equity Research AnalystDennis ...

Viking Therapeutics (NasdaqCM:VKTX) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsBrian Lian - President and CEOGreg Zante - CFONeil Aubuchon - Chief Commercial OfficerRohit Bhasin - Equity Research AssociateRyan Deschner - Senior Research AssociateStephanie Diaz - Manager of Investor RelationsTimur Ivannikov - Biotech AssociateConference Call ParticipantsAndy Hsieh - Partner and Senior Biotech AnalystAnnabel Samimy - Managing Director and Senior AnalystBiren Amin - Managing Direct ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $119.5 million, representing a 5% increase over 2024 [5][15] - Non-GAAP gross margin for the year increased by 400 basis points to 39.6%, with a target of reaching 50% in the future [16][17] - Non-GAAP operating loss decreased by 14% to $13.3 million compared to the previous year [15] Business Line Data and Key Metrics Changes - Product revenue for Q4 was $19.9 million, down from $21 million in the same quarter last year, with console sales growing 11% to $6.4 million [11][12] - Service and other revenue grew by 6% to $9 million, while recurring revenue from consumables and services was $22.5 million [12][16] - Product gross margin exceeded 50% for the first time, reaching 50.7% [14] Market Data and Key Metrics Changes - Tablo is now utilized in approximately 1,000 acute care sites across the U.S., with significant customer satisfaction scores above 95% [4][6] - The company has expanded its partnerships with acute and post-acute care providers, leading to improved clinical outcomes and operational benefits [6][7] Company Strategy and Development Direction - The company aims to enhance its technology and service leadership while reducing costs, as evidenced by the recent FDA clearance of the next-generation Tablo platform [3][9] - The focus is on insourcing dialysis services, which has shown to improve clinical outcomes and operational efficiencies for healthcare providers [6][19] - The company plans to launch the next-generation Tablo platform in Q2 2026, which is expected to provide a competitive advantage due to its compliance with stringent cybersecurity standards [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, anticipating revenue growth between $125 million and $130 million, a 5%-9% increase over 2025 [17][18] - The company expects to continue reducing cash usage and improving operating leverage, with operating expense growth anticipated to be half the rate of revenue growth [18][52] - Management highlighted the importance of cybersecurity in healthcare and how the new Tablo platform addresses these concerns, potentially attracting more customers [24][25] Other Important Information - The company ended Q4 with $173 million in cash and equivalents, indicating sufficient liquidity to reach profitability [15][52] - The company has made significant investments in innovation and talent acquisition to strengthen its leadership team [3][4] Q&A Session Summary Question: What advantages will the next-gen Tablo offer and how will it affect market opportunities? - Management indicated that the next-gen Tablo will enhance cybersecurity, which is a growing concern for hospitals, potentially attracting more customers [23][24] Question: What is the current state of the sales force and deal pipeline? - Management reported stability in the sales force and a healthy pipeline, with diversification across new and existing customers [26][30] Question: Can you quantify pipeline growth entering 2025 versus 2026? - Management noted similar growth rates in the pipeline between 2024 and 2025, indicating strong demand for their services [42] Question: What is the timeline for achieving 50% gross margin? - Management confirmed that reaching 50% gross margin is within their planning horizon, but did not specify a formal timeline [51] Question: How is the hospital capital budget environment currently? - Management stated that there have been no material changes in capital spending among their customers for 2026 [53]

Vanda Pharmaceuticals (NasdaqGM:VNDA) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsAndrew Tsai - Managing DirectorKevin Moran - CFOMihael Polymeropoulos - CEORaghuram Selvaraju - Managing DirectorConference Call ParticipantsMadison El-Saadi - Healthcare Research AnalystNone - AnalystOperatorThank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q4 2025 Vanda Pharmaceuticals Inc. earnings conferenc ...

AMC Networks (NasdaqGS:AMCX) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsKim Kelleher - Chief Commercial OfficerKristin Dolan - CEONick Seibert - Senior Vice President, Corporate Development and Investor RelationsPatrick O'Connell - CFOThomas Yeh - Executive Director in Equity ResearchConference Call ParticipantsDavid Joyce - Senior AnalystSteven Cahall - Senior AnalystOperatorGood day and thank you for standing by. Welcome to the AMC Networks fourth quarter 2025 earnings call. A ...

Fastly (NYSE:FSLY) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsFatima Boolani - Co Head of US Software Equity Research and Managing DirectorFrank Louthan - Managing Director of Equity ResearchJackson Ader - Managing DirectorJonathan Ho - PartnerKip Compton - CEORichard Wong - CFOVernon Essi - VP of Investor RelationsConference Call ParticipantsJeff Van Rhee - Partner and Equity Research AnalystParam Singh - Senior AnalystRudy Kessinger - Managing Director and Senior Equity Resear ...

Viking Therapeutics (NasdaqCM:VKTX) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsBarron Amon - Biotech Equity Research AssociateBrian Lian - President and CEOGreg Zante - CFONeil Aubuchon - Chief Commercial OfficerRohit Bhasin - Equity Research AssociateRyan Deschner - Senior Research AssociateStephanie Diaz - Manager of Investor RelationsTimur Ivannikov - Biotech AssociateConference Call ParticipantsAndy Hsieh - Partner and Senior Biotech AnalystAnnabel Samimy - Managing Director ...

Neurocrine Biosciences (NasdaqGS:NBIX) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsCorinne Johnson - Managing DirectorDanielle Brill - Managing DirectorEric Benevich - Chief Commercial OfficerKyle Gano - CEOLuke Lapointe - Director of Global Healthcare GroupMatt Abernethy - CFOMohit Bansal - Managing DirectorPaul Matteis - Managing Director and Head of Therapeutics ResearchPhil Nadeau - Managing Director and Head of Healthcare Equity ResearchSanjay Keswani - Chief Medical Officer ...

Ascendis Pharma (NasdaqGS:ASND) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsAlex Thompson - Managing DirectorChad Fugere - VP of Investor RelationsDerek Archila - Managing Director and Co-Head of Therapeutics ResearchHeidi Jacobson - Equity Research AssociateJan Møller Mikkelsen - President and CEOJay Wu - EVP and President of US MarketLeland Gershell - Managing DirectorMaxwell Skor - VP in Biotech Equity ResearchScott Smith - CFOConference Call ParticipantsDaniel Brander - Equit ...

McDonald’s (NYSE:MCD) Q4 2025 Earnings call February 11, 2026 04:30 PM ET Company ParticipantsChris Kempczinski - Chairman and CEODave Palmer - Senior Managing Director and the Head of the Consumer Research TeamDexter Congbalay - VP of Investor RelationsIan Borden - CFOJill McDonald - Executive Vice President and President of International Operated MarketsConference Call ParticipantsAndrew Barish - Equity Research AnalystBrian Harbour - Equity Research AnalystDavid Tarantino - Equity Research AnalystDennis ...